| Indication |
For the treatment of anorexia associated with weight loss in
patients with AIDS, and nausea and vomiting associated with cancer
chemotherapy in patients who have failed to respond adequately to
conventional antiemetic treatments |
| Pharmacodynamics |
Marinol may has complex effects on the central nervous system
(CNS), including cannabinoid receptors. Dronabinol may inhibit
endorphins in the emetic center, suppress prostaglandin synthesis,
and/or inhibit medullary activity through an unspecified cortical
action. |
| Mechanism of action |
The mechanism of action of marinol is not completely understood.
It is thought that cannabinoid receptors in neural tissues may mediate
the effects of dronabinol and other cannabinoids. Animal studies with
other cannabinoids suggest that marinol's antiemetic effects may be due
to inhibition of the vomiting control mechanism in the medulla
oblongata. |
| Absorption |
90 - 95% |
| Volume of distribution |
|
| Protein binding |
97% |
| Metabolism |
Hepatic |
| Route of elimination |
Dronabinol and its biotransformation products are excreted in both feces and urine. |
| Half life |
Alpha phase: approximately 4 hours; Beta phase: 25-36 hours |
| Clearance |
|
| Toxicity |
Not Available |
